Evaluate every Camp Lejeune claim against both recovery tracks.

The Camp Lejeune Justice Act of 2022 (CLJA), signed as part of the Honoring Our PACT Act, created the first legal right for individuals to sue the federal government for injuries caused by decades of toxic water contamination at Camp Lejeune and Marine Corps Air Station New River. Between 1953 and 1987, the water supply was contaminated with volatile organic compounds including trichloroethylene (TCE), tetrachloroethylene (PCE), vinyl chloride, and benzene at levels far exceeding safe exposure thresholds. Over 500,000 administrative claims were filed before the August 2024 deadline. All CLJA lawsuits are consolidated in the Eastern District of North Carolina.

CLJ claimants have two distinct paths. The Elective Option (EO) is a government-administered fixed-payout program that pays based on injury tier and cumulative exposure duration, with a maximum payout of $550,000. The active federal litigation track offers no fixed compensation but allows claimants to pursue individualized damages. Accepting an EO offer waives the right to pursue the litigation track. Pattern evaluates both paths simultaneously from a single case view, so firms can counsel clients on the tradeoff without rebuilding the case file.

The EO covers nine conditions across two tiers. Tier 1 — the highest-value category — includes kidney cancer, liver cancer, non-Hodgkin's lymphoma, leukemia, bladder cancer, Parkinson's disease, and multiple myeloma. Tier 2 includes aplastic anemia and myelodysplastic syndromes, Stage 4–5 chronic kidney disease, and systemic scleroderma. Conditions outside these nine can be pursued through the litigation track under the CLJA's broader "at least as likely as not" causation standard.

All CLJ injuries are subject to a two-sided latency window: diagnosis or first treatment must occur at least two years after first exposure and no more than 35 years after last exposure. For EO purposes, the injury must also have been diagnosed or treated before August 10, 2022. These three conditions must be validated per injury entry — not just at the case level. A claimant with multiple qualifying injuries may have one that passes the latency window and one that does not. Pattern validates all three conditions independently per injury and flags the specific disqualifying condition when any window is missed.

Two conditions are regularly miscategorized. First, kidney disease: EO Tier 2 qualification requires Stage 4 or higher CKD specifically. A general kidney disease diagnosis or a Stage 3 entry does not qualify. Second, scleroderma: only systemic forms qualify under the EO. Localized scleroderma does not, but rheumatology records do not always specify the distinction clearly. Pattern captures CKD stage per injury entry and flags every scleroderma entry with a prompt to confirm systemic versus localized form before EO evaluation proceeds.

For EO-track claimants, official documentation of base presence is required — affidavits and sworn declarations are not sufficient. Accepted record types include DD-214 military discharge records, housing and base assignment records, VA records, financial records, and relationship documentation for dependent family members. Pattern captures record type per exposure entry and flags when the only available evidence is an affidavit, giving firms clear visibility into which cases need official records before an EO offer can be evaluated.

Every CLJ claimant receives a Pattern Development Case Score on a 0–6 scale based on the strength of their evidentiary record — exposure validity, injury confirmation, timeline integrity, treatment severity, and death documentation. The score is independent of formal EO eligibility. It gives firms a consistent case strength signal across the entire inventory today, before global litigation-track settlement criteria are announced and before resources are committed to cases that won't hold up.